Evaluator Training and Reliability for SMA Global Nusinersen Trials
Open Access
- 29 May 2018
- journal article
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 5 (2) , 159-166
Abstract
Background: Training methodology was established to optimize reliability of outcome measures in the nusinersen clinical trials. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Hammersmith Functional Motor Scale Expanded (HFMSE), and Revised Upper Limb (RULM) were primary or secondary outcomes. Methods: Video review, quarterly conference calls, and item scoring checks supported evaluator competence. Baseline and screening along with video review established intra and inter-rater reliability. Results: Inter and intra-rater reliability were both excellent. Intraclass correlation coefficients (ICC) ranged between 0.906–0.994 across initial training meetings and 0.824–0.996 across annual retraining meetings. This was similar for CHOP INTEND (ICC = 0.824–0.951), HFMSE (ICC = 0.981–0.996), and RULM (ICC = 0.966–0.990). Intra-rater reliability for the CHOP INTEND, HFMSE, and RULM were ICC = 0.895 (95% CI: 0.852–0.926; n = 116), ICC = 0.959 (95% CI: 0.942–0.971; n = 125), and ICC = 0.948 (95% CI: 0.927–0.963; n = 126) respectively. Conclusions: Rigorous evaluator training ensures reliability of assessment of subjects with spinal muscular atrophy (SMA) in multicenter international trials.Keywords
This publication has 11 references indexed in Scilit:
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- Revised upper limb module for spinal muscular atrophy: Development of a new moduleMuscle & Nerve, 2016
- Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophyNeurology, 2016
- Spinal Muscular AtrophiesPediatric Clinics of North America, 2015
- Observational study of spinal muscular atrophy type I and implications for clinical trialsNeurology, 2014
- Prospective cohort study of spinal muscular atrophy types 2 and 3Neurology, 2012
- Antisense-based therapy for the treatment of spinal muscular atrophyJournal of Cell Biology, 2012
- Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and IIIJournal of Child Neurology, 2011
- The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliabilityNeuromuscular Disorders, 2010
- An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patientsNeuromuscular Disorders, 2007